For the quarter ending 2026-03-31, TBPH had $120,295K increase in cash & cash equivalents over the period.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Loss from operations | - | 20,011 | - | - |
| Net gain on realized contingent milestone and royalty assets | - | 0 | - | - |
| Trelegy milestone income | - | 50,000 | - | - |
| Interest expense (non-cash) | - | 582 | - | - |
| Interest and other income, net | - | 3,639 | - | - |
| Provision for income tax benefit (expense) | - | 12,044 | - | - |
| Prepaid clinical and development services | - | 0 | 0 | -73 |
| Net loss | -4,933 | 61,024 | 3,615 | 41,256 |
| Future contingent milestone and royalty assets | - | 0 | 0 | -144,200 |
| Depreciation and amortization | 381 | 399 | 405 | 822 |
| Amortization and accretion on investment securities, net | 602 | 1,310 | 771 | 749 |
| Future royalty payment contingency interest accretion | - | 582 | 573 | 1,306 |
| Share-based compensation | 4,504 | 4,480 | 4,576 | 9,420 |
| Loss on disposal of property and equipment | - | 0 | 0 | -35 |
| Amortization of right-of-use assets | 1,056 | 1,107 | 1,002 | 1,906 |
| Deferred income taxes | -2,999 | 30 | 994 | -12,543 |
| Other | -42 | -6 | 22 | 73 |
| Receivables from collaborative and licensing arrangements | -29,954 | 27,272 | -3,652 | 3,479 |
| Receivables from milestones and royalty assets | 0 | - | 0 | -50,000 |
| Other prepaid and current assets | -1,666 | 814 | 1,179 | 1,367 |
| Right-of-use lease assets | -314 | 28 | -41 | 45 |
| Income tax payable | - | - | -22,622 | 20,843 |
| Other assets | -1,025 | -251 | 413 | 915 |
| Accounts payable | -1,468 | 355 | 538 | -567 |
| Accrued personnel-related expenses, accrued clinical and development expenses, and other accrued liabilities | -4,867 | -1,275 | 3,606 | 1,678 |
| Operating lease liabilities | -2,199 | -1,892 | -1,862 | -3,363 |
| Unrecognized tax benefits | 1,474 | 6,515 | 1,360 | 2,606 |
| Other long-term liabilities | -69 | -1 | -1 | 69 |
| Net cash provided by operating activities | 73,279 | -6,064 | -6,508 | 251,113 |
| Purchases of property and equipment | - | 8 | 0 | 34 |
| Purchases of marketable securities | 43,407 | 64,929 | 124,746 | 58,542 |
| Maturities of marketable securities | 96,000 | 65,525 | 24,500 | 52,950 |
| Net cash provided by investing activities | 52,593 | 588 | -100,246 | -5,626 |
| Proceeds from the sale of ordinary shares | - | 0 | 0 | 20 |
| Proceeds from option exercises | 241 | 488 | 278 | - |
| Repurchase of shares to satisfy tax withholding | 5,818 | 1,979 | 678 | 1,377 |
| Net cash used in financing activities | -5,577 | -1,491 | -400 | -1,357 |
| Net increase in cash, cash equivalents, and restricted cash | 120,295 | -6,967 | -107,154 | 244,130 |
| Cash, cash equivalents, and restricted cash at beginning of period | 168,642 | 175,609 | 38,633 | - |
| Cash, cash equivalents, and restricted cash at end of period | 288,937 | 168,642 | 175,609 | - |
Theravance Biopharma, Inc. (TBPH)
Theravance Biopharma, Inc. (TBPH)